Skip to main content

NYSEAMERICAN:CRMD - CorMedix Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.90
  • Forecasted Upside: 203.86 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$6.22
▲ +0.17 (2.81%)
1 month | 3 months | 12 months
Get New CorMedix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRMD

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$18.90
▲ +203.86% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for CorMedix in the last 3 months. The average price target is $18.90, with a high forecast of $29.00 and a low forecast of $10.00. The average price target represents a 203.86% upside from the last price of $6.22.

Buy

The current consensus among 5 contributing investment analysts is to buy stock in CorMedix. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/21/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/19/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/17/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/14/2021Needham & Company LLCLower Price TargetBuy$31.00 ➝ $29.00
i
3/2/2021B. RileyReiterated RatingBuy$25.00 ➝ $13.50
i
2/17/2021Needham & Company LLCInitiated CoverageBuy$31.00
i
11/19/2020HC WainwrightReiterated RatingBuy
i
9/29/2020JMP SecuritiesInitiated CoverageMarket Outperform$22.00
i
9/21/2020TruistInitiated CoverageBuy$20.00
i
8/25/2020HC WainwrightReiterated RatingBuy$10.00
i
8/11/2020HC WainwrightLower Price TargetBuy$14.00 ➝ $10.00
i
7/9/2020HC WainwrightReiterated RatingBuy
i
Rating by Ram Selvaraju at HC Wainwright
5/12/2020B. RileyBoost Price TargetBuy$10.00 ➝ $12.00
i
Rating by A. D'silva at B. Riley
3/18/2020B. RileyLower Price TargetBuy$15.00 ➝ $10.00
i
Rating by A. D'silva at B. Riley
3/18/2020HC WainwrightReiterated RatingBuy$14.00
i
Rating by Ram Selvaraju at HC Wainwright
2/4/2020HC WainwrightReiterated RatingBuy$14.00
i
Rating by Ram Selvaraju at HC Wainwright
12/18/2019B. RileyReiterated RatingBuy
i
Rating by A. D'silva at B. Riley
12/18/2019B. RileyInitiated CoverageBuy$48.00
i
Rating by A. D'silva at B. Riley
12/2/2019HC WainwrightReiterated RatingBuy$14.00
i
Rating by Ram Selvaraju at HC Wainwright
5/28/2019HC WainwrightSet Price TargetBuy$14.00
i
Rating by Ram Selvaraju at HC Wainwright
3/18/2019HC WainwrightSet Price TargetBuy$15.00
i
Rating by Ram Selvaraju at HC Wainwright
1/18/2019HC WainwrightReiterated RatingBuy$17.50
i
Rating by Ram Selvaraju at HC Wainwright
12/12/2018HC WainwrightReiterated RatingBuy$17.50
i
Rating by Ram Selvaraju at HC Wainwright
12/6/2018Roth CapitalReiterated RatingBuy$6.00
i
Rating by J. Isaacson at Roth Capital
12/6/2018Roth CapitalInitiated CoverageBuy ➝ Buy$30.00
i
Rating by J. Isaacson at Roth Capital
10/15/2018HC WainwrightSet Price TargetBuy$15.00
i
Rating by Ram Selvaraju at HC Wainwright
8/15/2018HC WainwrightSet Price TargetBuy$15.00
i
Rating by Ram Selvaraju at HC Wainwright
7/26/2018HC WainwrightSet Price TargetBuy$15.00
i
Rating by Ram Selvaraju at HC Wainwright
5/23/2018HC WainwrightSet Price TargetBuy ➝ Buy$20.00 ➝ $10.00
i
Rating by Ram Selvaraju at HC Wainwright
4/2/2018HC WainwrightSet Price TargetBuy$20.00
i
Rating by Ram Selvaraju at HC Wainwright
10/16/2017HC WainwrightSet Price TargetBuy$20.00
i
Rating by R. Selvaraju at HC Wainwright
9/25/2017HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $20.00
i
Rating by R. Selvaraju at HC Wainwright
8/10/2017Rodman & RenshawLower Price TargetBuy ➝ Buy$25.00 ➝ $15.00
i
8/10/2017HC WainwrightSet Price TargetBuy$15.00
i
5/5/2017Rodman & RenshawLower Price TargetBuy$30.00 ➝ $25.00
i
4/24/2017(FBRC)Reiterated RatingBuy
i
2/22/2017(FBRC)Set Price TargetBuy$20.00
i
11/11/2016(FBRC)Lower Price TargetOutperform$30.00 ➝ $20.00
i
(Data available from 5/18/2016 forward)
CorMedix logo
CorMedix, Inc. operates as a pharmaceutical and medical device company. The firm seeks to license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.
Read More

Today's Range

Now: $6.22
$5.53
$6.22

50 Day Range

MA: $7.89
$7.38
$8.46

52 Week Range

Now: $6.22
$3.75
$18.80

Volume

674,952 shs

Average Volume

1,037,847 shs

Market Capitalization

$236.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.71

Frequently Asked Questions

What sell-side analysts currently cover shares of CorMedix?

The following Wall Street sell-side analysts have issued stock ratings on CorMedix in the last year: B. Riley, HC Wainwright, JMP Securities, Needham & Company LLC, Truist, and Zacks Investment Research.
View the latest analyst ratings for CRMD.

What is the current price target for CorMedix?

5 Wall Street analysts have set twelve-month price targets for CorMedix in the last year. Their average twelve-month price target is $18.90, suggesting a possible upside of 203.9%. Needham & Company LLC has the highest price target set, predicting CRMD will reach $29.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $10.00 for CorMedix in the next year.
View the latest price targets for CRMD.

What is the current consensus analyst rating for CorMedix?

CorMedix currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRMD will outperform the market and that investors should add to their positions of CorMedix.
View the latest ratings for CRMD.

What other companies compete with CorMedix?

How do I contact CorMedix's investor relations team?

CorMedix's physical mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company's listed phone number is (908) 517-9500. The official website for CorMedix is www.cormedix.com.